Number of the records: 1  

Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients

  1. 1.
    0379059 - BTÚ 2013 RIV US eng J - Journal Article
    Tomasetti, M. - Staffolani, S. - Nocchi, L. - Neužil, Jiří - Strafella, E. - Manzella, N. - Mariotti, L. - Bracci, M. - Matteo, V.A. - Amati, M. - Santarelli, L.
    Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients.
    Clinical Biochemistry. Roč. 45, 7-8 (2012), s. 575-581. ISSN 0009-9120. E-ISSN 1873-2933
    R&D Projects: GA ČR(CZ) GA204/08/0811
    Institutional research plan: CEZ:AV0Z50520701
    Keywords : Circulating miRNA markers * relative qRT-PCR * pleural mesothelioma
    Subject RIV: EB - Genetics ; Molecular Biology
    Impact factor: 2.450, year: 2012

    Objectives: Aim of this study was to evaluate the accuracy and precision of the detection of individual miRNA as clinical biomarkers in the serum. Design and methods: miRNA-126 was quantified in serum using endogenous and exogenous controls for normalization and the accuracy and precision of the method evaluated. The diagnostic value of serum miRNA-126 was evaluated in malignant mesothelioma (MM) and non-small-cell lung cancer (NSCLC) patients using both relative and absolute qRT-PCR methods. Results: The use of endogenous invariant and exogenous synthetic controls as well sample dilution markedly improves the accuracy and precision of the assay. The inter- and intra-assay analyses revealed that relative qRT-PCR is a more reliable method. Circulating miR-126 detected in the serum by relative qRT-PCRs was found low-expressed in both malignancies, significantly differentiated MM patients from healthy controls and NSCLC from MM, but do not discriminate NSCLC patients from control subjects. Kaplan-Meier analysis revealed that low level of circulating miR-126 in MM patients was strongly associated with worse prognosis. Conclusions: We propose that this approach can be adopted for accurate analysis of other suitable circulating miRNA markers of different types of cancer. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
    Permanent Link: http://hdl.handle.net/11104/0210337

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.